Genetically engineered and phenotyped mice and stem cell clones for producing the same

1 . A transgenic mouse whose genome comprises a disruption of a gene and wherein said disruption results in a phenotype that differs form the phenotype of a wild-type mouse, said gene selected from the group consisting of:

a. a gene comprising SEQ ID NO:9, wherein the disruption of the gene comprising SEQ ID NO:9 results in decreased depressive-like response in (−/−) mice;

b. a gene comprising SEQ ID NO:10, wherein the disruption of the gene comprising SEQ ID NO:10 results increased artery-to-vein ratios in (−/−) mice;

c. a gene comprising SEQ ID NO:11, wherein the disruption of the gene comprising SEQ ID NO:11 results in infertile female (−/−) mice exhibiting ovarian hypoplasia;

d. a gene comprising SEQ ID NO:12, wherein the disruption of the gene comprising SEQ ID NO:12 results in an increased percentage of natural killer cells in (−/−) mice;

e. a gene comprising SEQ ID NO:14, wherein the disruption of the gene comprising SEQ ID NO:14 results in a decreased percentage of CD8 cells and an increased percentage of B cells in the peripheral blood of (−/−) mice;

f. a gene comprising SEQ ID NO:15, wherein the disruption of the gene comprising SEQ ID NO:15 results in compensated hemolytic anemia in (−/−) mice;

g. a gene comprising SEQ ID NO:16, wherein the disruption of the gene comprising SEQ ID NO:16 results in decreased bone mineral content and density in (−/−) mice;

h. a gene comprising SEQ ID NO:17, wherein the disruption of the gene comprising SEQ ID NO:17 results in decreased red blood cell count in (−/−) mice;

i. a gene comprising SEQ ID NO:18, wherein the disruption of the gene comprising SEQ ID NO:18 results in an increased percentage of NK cells in (−/−) mice;

j. a gene comprising SEQ ID NO:19, wherein the disruption of the gene comprising SEQ ID NO:19 results in increased serum IgG1 and IgG2a responses to ovalbumin challenge in (−/−) mice;

k. a gene comprising SEQ ID NO:20, wherein the disruption of the gene comprising SEQ ID NO:20 results in enhanced learning/memory in male (−/−) mice;

l. a gene comprising SEQ ID NO:21, wherein the disruption of the gene comprising SEQ ID NO:21 results in small male (−/−) mice, exhibiting a decreased fasting serum glucose level;

m. a gene comprising SEQ ID NO:22, wherein the disruption of the gene comprising SEQ ID NO:22 results in impaired sensorimotor gating/attention in (−/−) mice;

n. a gene comprising SEQ ID NO:23, wherein the disruption of the gene comprising SEQ ID NO:23 results in immunological abnormalities in (−/−) mice;

o. a gene comprising SEQ ID NO:24, wherein the disruption of the gene comprising SEQ ID NO:24 results in decreased pain response in (−/−) mice; and

p. a gene comprising SEQ ID NO:25, wherein the disruption of the gene comprising SEQ ID NO:25 results in increased serum glucose levels in (+/−) and (−/−) animals.

2 . A mouse, said mouse being off-spring of a mouse according to claim 1 .

3 . An isolated cell, said cell being derived from a mouse according to claim 1 .

4 . The cell according to claim 3 , said cell being selected from the group consisting of a stem cell, an embryonic stem cell, a hematopoietic stem cell, a progenitor cell, a fibroblast, a nerve cell, a muscle cell, an epithelial cell, and a teratocarcinoma cell.

5 . An isolated antibody, said antibody being prepared by introducing an antigen into a mouse according to claim 1 .

6 . An isolated antibody, said antibody being derived from an antibody according to claim 5 and said antibody being selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a multispecific antibody, a human antibody, a humanized antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′) fragment, a fragment produced by a Fab expression library, an anti-idiotypic (anti-Id) antibody, and an epitope-binding fragments of an antibody.